RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease

This study has been terminated.
Sponsor:
Information provided by:
Repligen Corporation
ClinicalTrials.gov Identifier:
NCT00060515
First received: May 7, 2003
Last updated: August 4, 2005
Last verified: August 2005
  Purpose

The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.


Condition Intervention Phase
Mitochondrial Diseases
Drug: RG2133 (2',3',5'-tri-O-acetyluridine)
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Primary Purpose: Treatment
Official Title: An Open-Label Dose-Escalation Phase I Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RG2133 (2',3',5'-Tri-O-Acetyluridine) in the Treatment of Inherited Mitochondrial Diseases

Resource links provided by NLM:


Further study details as provided by Repligen Corporation:

Estimated Enrollment: 12
  Eligibility

Ages Eligible for Study:   3 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Mitochondrial Disease

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00060515     History of Changes
Other Study ID Numbers: RG2133-01
Study First Received: May 7, 2003
Last Updated: August 4, 2005
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Mitochondrial Diseases
Metabolic Diseases

ClinicalTrials.gov processed this record on August 26, 2014